Key Highlights

  • NewAmsterdam Pharma (NASDAQ:NAMS) generated USD 19.2 million in Revenue for the third quarter, up from about USD 0.3 million the prior year, with USD 18.3 million coming from licensing.
  • Tenaya Therapeutics (NASDAQ:TNYA) carried a USD 18.9 million net loss, or USD 0.08 a share, holding USD 66.8 million in cash and equivalents alongside 148.0 million securities that could dilute holders.
  • Solid Biosciences (NASDAQ:SLDB) absorbed a USD 53.9 million loss, or USD 0.36 a share, while USD 348.9 million on hand is expected by management to cover operations through the first half of 2028.
  • OnKure Therapeutics (NASDAQ:OKUR) saw its net loss grow to USD 17.8 million, yet USD 163.3 million of cash and securities is projected by management to sustain operations until 2029.

NewAmsterdam Pharma (NASDAQ:NAMS): Licensing Income Drives the Quarter, Product Sales Do Not

NewAmsterdam Pharma (NASDAQ:NAMS) is a late-stage biopharmaceutical company developing obicetrapib, an oral cholesterol-lowering candidate, and its third-quarter report went out on November 4, 2026. Top-line revenue hit USD 19.2 million, while the year-earlier figure was about USD 0.3 million; USD 18.3 million of the current total came from license income. Nine-month revenue totaled USD 25.9 million, up from USD 22.5 million, which suggests the quarter's jump is partly a matter of timing. The company lost USD 17.4 million this quarter, which is USD 0.14 a share, compared with USD 72.0 million in the prior-year period, largely because Warrant Revaluation produced a USD 23.1 million gain where a USD 23.8 million loss had been booked before, a swing worth USD 46.9 million on simple arithmetic. Research and Development rose to USD 39.4 million, and nine-month losses stood at USD 130.0 million, compared with USD 128.9 million, showing no narrowing. Cash, cash equivalents and marketable securities came to USD 643.1 million. Ubeslo and Evlarco received European Commission Marketing approval in September 2026, and Menarini is set to start sales in Germany before the end of the year. A PREVAIL outcomes trial interim review is set for the fourth quarter, and the filing offers no price move or consensus figure.

Tenaya Therapeutics (NASDAQ:TNYA): Modest Cash Set Against a Heavy Warrant Overhang

Tenaya Therapeutics (NASDAQ:TNYA) put its third-quarter 2026 numbers on record November 4, 2026. This clinical-stage developer is working on inherited heart disease treatments and sells no approved products. The loss narrowed to USD 18.9 million, equal to USD 0.08 per share, down from USD 20.3 million, or USD 0.12, with USD 1.7 million of collaboration revenue offsetting part of the spending. Part of the per-share improvement comes from weighted average shares rising to 226.0 million from 163.3 million. Operating expenses totaled USD 21.3 million, and cash and cash equivalents stood at USD 66.8 million. Dividing that cash by quarterly operating expenses yields about 3.1 quarters, a number we derived ourselves, not one the company published, because the filing extract contains no runway figure. Potentially dilutive instruments total 148.0 million, among them 75.0 million Series A and B warrants, so exercises or new financing would enlarge the share count. The Alnylam Pharmaceuticals collaboration, struck in March 2026, pays USD 10 million up front with milestone payments reaching USD 1.1 billion. In the fourth quarter the company expects to publish follow-up on TN-201 and TN-401, alongside a regulatory update.

Solid Biosciences (NASDAQ:SLDB): Gene Therapy Spending Meets a Late-2026 FDA Meeting

Solid Biosciences (NASDAQ:SLDB) released its quarterly numbers on November 4, 2026. The company builds gene therapies for rare neuromuscular and cardiac diseases, with SGT-003 for Duchenne muscular dystrophy as the lead program. For the third quarter the net loss reached USD 53.9 million, or USD 0.36 a share, up from USD 45.8 million, or USD 0.48, a year earlier. Research and development climbed 12.2% to USD 43.6 million, General and administrative spending, by contrast, reached USD 14.1 million, up from USD 9.2 million. Liquidity of USD 348.9 million, made up of cash, cash equivalents and available-for-sale securities, is expected to cover operations into the first half of 2028. The company has a Type C session with the FDA lined up for the final weeks of 2026, aimed at a possible Accelerated Approval route for SGT-003. Safety data as of November 3, 2026 show that SGT-003 was generally well tolerated among 53 people dosed, and two treatment-related serious adverse events had already been disclosed. The accumulated Deficit reached USD 1.1 billion. Over the quarter, 2.0 million shares were placed via the at-the-market program, and 4.3 million more came from pre-funded warrant exercises; both routes add to the share count. Management expects significant losses to continue and says substantial additional funding is required.

OnKure Therapeutics (NASDAQ:OKUR): Placement Proceeds Erase Going-Concern Doubt and Fund Operations Into 2029

OnKure Therapeutics (NASDAQ:OKUR) published quarterly results on November 4, 2026. This clinical-stage developer creates small molecules aimed at mutated forms of PI3K alpha, a protein involved in cancer growth signaling; the normal form is left alone. Quarterly losses grew from a year earlier: USD 17.8 million, or USD 0.36 a share, versus USD 14.7 million, or USD 1.09 a share, a prior-year per-share figure the singles report as filed without reconciling the share count. Research and development spending moved up to USD 15.1 million, compared with USD 11.9 million before, an increase of about 26% by simple arithmetic, driven by outsourced preclinical work and manufacturing. The private placement that closed on March 31, 2026 raised about USD 150.0 million gross. Management had flagged substantial doubt about continuing operations as of December 31, 2025, and after the placement it said that doubt had been alleviated. Management expects the USD 163.3 million of cash and marketable securities to fund operations into 2029. Plans call for Investigational New Drug submissions on two candidates in the first half of 2027: OKI-345, aimed at breast cancer, and OKI-355, aimed at vascular anomalies. Options covering about 1.7 million shares were repriced to USD 4.14 on August 7, 2026. Management adds that substantial further Capital will be needed, and Equity sales would dilute holders.

Where Things Stand

Not at this stage. The USD 19.2 million at NewAmsterdam Pharma (NASDAQ:NAMS) reflects one large licensing item landing in the quarter, not product sales ramping up. The company also booked a USD 23.1 million warrant gain, while its nine-month loss stayed roughly flat. The other three still depend on outside money to finance their plans. Tenaya Therapeutics (NASDAQ:TNYA) has USD 66.8 million on hand alongside a large stack of warrants. Solid Biosciences (NASDAQ:SLDB) signals runway into the first half of 2028 and holds a late fourth-quarter FDA meeting. OnKure Therapeutics (NASDAQ:OKUR) signals 2029 and intends two regulatory submissions in the first half of 2027. Next catalysts: the German launch, the PREVAIL interim review, the SGT-003 FDA meeting and whatever financing comes next.